Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement
Article first published online: 15 JUL 2010
DOI: 10.1111/j.1468-1331.2010.03130.x
© 2010 The Author(s). Journal compilation © 2010 EFNS
Issue

European Journal of Neurology
Special Issue: Botulinum Toxin Consensus Statement
Volume 17, Issue Supplement s2, pages 94–108, August 2010
Additional Information
How to Cite
Novak, I., Campbell, L., Boyce, M. and Fung, V. S. C. (2010), Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement. European Journal of Neurology, 17: 94–108. doi: 10.1111/j.1468-1331.2010.03130.x
Publication History
- Issue published online: 15 JUL 2010
- Article first published online: 15 JUL 2010
- Received 9 July 2009 Accepted 14 May 2010
- Abstract
- Article
- References
- Cited By
Keywords:
- assessment;
- botulinum toxin A;
- cervical;
- dystonia;
- hypertonicity;
- neck;
- systematic review;
- therapy
Dystonia in the neck region can be safely and effectively reduced with injections of Botulinum neurotoxin-A and B. People with idiopathic cervical dystonia have been studied the most. Benefits following injection include increased range of movement at the neck for head turning, decreased pain, and increased functional capacity (Class I evidence, level A recommendation). The evidence for efficacy and safety in patients with secondary dystonia in the neck is unclear based on the lack of rigorous research conducted in this heterogeneous population (level U recommendation). Psychometrically sound assessments and outcome measures exist to guide decision-making (Class I evidence, level A recommendation). Much less is known about the effectiveness of therapy to augment the effects of the injection (Class IV, level U recommendation). More research is needed to answer questions about safety and efficacy in secondary spastic neck dystonia, effective adjunctive therapy, dosing and favourable injection techniques.

1468-1331/asset/olbannerleft.jpg?v=1&s=5d3a3e0b13870c31eb751e2f9ac484568b81fd0e)